**04-78000-16**

**Original Effective Date: 06/15/01**

**Reviewed: 02/27/20**

**Revised:** 03/25/20

# Subject: Positron Emission Tomography (PET ) Cardiac Applications

**THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.**



## DESCRIPTION:

Positron emission tomography (PET) scans are based on the use of positron emitting radionuclide tracers, which simultaneously emit 2 high energy photons in opposite directions. These photons can be simultaneously detected (referred to as coincidence detection) by a PET scanner, consisting of multiple stationary detectors that encircle the thorax. Compared to single photon emission photon emission computed tomography (SPECT) scans, coincidence detection offers greater spatial resolution.

A variety of radiopharmaceuticals (tracers, radiotracers) are used for PET scanning, (e.g., e.g., ammonia N-13, Fluorodeoxyglucose F-18 FDG, Rubidium Rb-82). Because of their short half-life, radiopharmaceuticals must be made locally. With the exception of fluorine and rubidium, radiopharmaceuticals must be manufactured with an on-site cyclotron.

## POSITION STATEMENT:

Myocardial imaging positron emission tomography (PET) with FDA approved radioisotope **meets the definition of medical necessity** for the following:

### Suspected coronary artery disease (CAD)

When neither stress echocardiography (SE) nor myocardial perfusion imaging (MPI) have provided or are expected to provide optimal imaging.

### Symptomatic members without known CAD

- Previously unevaluated electrocardiogram (ECG) evidence of possible myocardial ischemia including substantial ischemic ST segment or T wave abnormalities.
- Previously unevaluated pathologic Q waves.

- Unevaluated complete left bundle branch bloc.

**Inconclusive CAD evaluation within the past 2 years and obstructive cad remains a concern** (When neither SE nor MPI have provided or are expected to provide optimal imaging)

- Exercise stress ECG with low risk Duke treadmill score (≥5), but member's current symptoms indicate an intermediate or high pretest probability.
- Exercise stress ECG with an intermediate Duke treadmill score.
- Inconclusive/borderline coronary computed tomography angiography (CCTA) (e.g. 40 - 70% lesions).
- Non-diagnostic exercise stress test with physical inability to achieve target heart rate (THR).
- An intermediate evaluation by prior stress imaging (within the past 2 years).

**Follow-up of members post coronary revascularization (PCI or CABG)** (when LVEF is ≤ 40% and revascularization is under consideration)

- Asymptomatic, follow-up stress imaging at a minimum of 2 years post coronary artery bypass grafting (CABG), or percutaneous coronary intervention (PCI), (whichever is later), is appropriate only for patients with a history of silent ischemia, or a history of a prior left main stent; **OR**
- For members with high occupational risk (e.g., associated with public safety, airline and boat pilots, bus and train drivers, bridge and tunnel workers/toll collectors, police officers, firefighters)
- New, recurrent, or worsening symptoms post coronary revascularization, is an indication for stress imaging, if it will alter management.

Follow-up of known CAD (When neither SE nor MPI have provided or are expected to provide optimal imaging)

- Routine follow-up of asymptomatic or stable symptoms when last invasive or non-invasive assessment of coronary disease showed hemodynamically significant CAD (ischemia on stress test or FFR ≤ 0.80 or stenosis greater than or equal to 70% of a major vessel), over two years ago, without intervening coronary revascularization is an appropriate indication for stress imaging in patients if it will alter management.

**Special diagnostic conditions requiring coronary evaluation** (When neither SE nor MPI have provided or are expected to provide optimal imaging)

- Prior acute coronary syndrome (as documented in physician notes), without subsequent invasive or non-invasive coronary evaluation.
- Newly diagnosed systolic heart failure (EF < 50%), especially with symptoms or signs of ischemia unless invasive coronary angiography is immediately planned.
- Reduced LVEF ≤ 50% requiring myocardial viability assessment to assist with decisions regarding coronary (Diversion from PET not required when LVEF less than or equal to 40%).
- Ventricular arrhythmias.
    - Sustained ventricular tachycardia (VT) > 100 bpm, ventricular fibrillation (VF), or exercise induced VT, when invasive coronary arteriography is not the immediately planned test
    - Nonsustained VT, multiple episodes, each ≥ 3 beats at ≥ 100 bpm, frequent PVC's (defined as greater than or equal to 30/hour) without known cause or associated cardiac pathology, when an exercise ECG cannot be performed
- Prior to Class IC antiarrhythmic drug initiation (Propafenone or Flecanide), in intermediate and high global risk patients (SE diversion not required)

- Assessment of hemodynamic significance of one of the following documented conditions:
  - Anomalous coronary arteries
  - Muscle bridging of coronary artery (perform with exercise stress).
- Coronary aneurysms in Kawasaki's disease or due to atherosclerosis.
- Following radiation therapy to the anterior or left chest, at 5 years post initiation and every 5 years thereafter.
- Cardiac sarcoidosis
  - Evaluation and therapy monitoring in patients with sarcoidosis, after documentation of suspected cardiac involvement by echo or ECG, when CMR has not been performed.
  - Evaluation of suspected cardiac sarcoid, after CMR has shown equivocal or negative findings in the setting of a high clinical suspicion
- Evaluation of CMR findings showing highly probable cardiac sarcoidosis, when PET could serve to identify inflammation and the consequent potential role for immunosuppressive therapy
  - Initial and follow up PET in monitoring therapy for cardiac sarcoid with immunosuppressive therapy, typically about 4 times over 2 years
- Infective endocarditis
  - In suspected infective endocarditis with moderate to high probability (i.e. staph bacteremia, fungemia, prosthetic heart valve, or intracardiac device), when TTE and TEE have been inconclusive with respect to diagnosis of infective endocarditis or characterization of paravalvular invasive complications
- Aortitis
  - For diagnosis and surveillance of ortitis, PET/CT or PET/MRI hybrid imaging.
- Members who have no other indication for a non-invasive coronary evaluation, but are referred for preoperative cardiac evaluation, are eligible for myocardial perfusion imaging (MPI) when ALL of the following criteria are met:
  - Surgery is supra-inguinal vascular, intrathoracic, or intra-abdominal; **AND**
  - The member has at least one of the additional cardiac complication risk factors:
    - Ischemic heart disease
    - History of stroke or TIA
    - History of congestive heart failure or ejection fraction ≤ 35%
    - Insulin-requiring diabetes mellitus
    - Creatinine ≥ 2.0 mg/dl

    **AND**
- The member has limited functional capacity (< 4 METS), such as one of the following:
    - Unable to take care of their activities of daily living (ADLs) or ambulate
    - Unable to walk 2 blocks on level ground
    - Unable to climb 1 flight of stairs.

    **AND**

- There has not been a conclusive stress evaluation, CTA, or heart catheterization within the past year, and the results of such a test would be likely to substantially alter therapy and/or preclude proceeding with the intended surgery.
- Planning for solid organ transplantation is an indication for preoperative MPI, if there has not been a conclusive stress evaluation, CTA, or heart catheterization within the past year and one of the following: (SE diversion not required)
    - The member has limited functional capacity (< 4 METS), such as **ONE** of the following:
        - Unable to take care of their ADLs or ambulate
        - Unable to walk 2 blocks on level groun
        - Unable to climb 1 flight of stairs.

      **OR**
    - In a member with ≥ 3 of the following:
        - Age > 60
        - Smoking
        - Hypertension
        - Dyslipidemia
        - Left ventricular hypertrophy
        - 1 year on dialysis (for renal transplant members)
        - Diabetes mellitus
        - Prior ischemic heart disease.

**Post cardiac transplant** (SE diversion not required)

- Annually, for the first five years post cardiac transplantation, in patient who otherwise will not undergo annual invasive coronary arteriography.
- After the first five years post cardiac transplantation:
    - Members with documented transplant coronary vasculopathy, can be screened annually if the risk of annual invasive coronary arteriography is not acceptable (e.g. high risk of contrast nephropathy) or not desired
- PET is indicated when ALL of the following criteria for MPI is met; **OR**
    - BMI > 40; **OR**
    - There is likely to be equivocal imaging results because of BMI or large breasts or implants or prior thoracic surgery or results of a prior MPI.
- For assessment of suspected significant hibernating myocardium in the presence of known severe major vessel CAD, when ejection fraction (EF) is below 40%, in order to determine a member's potential benefit from coronary revascularization.
- When strong suspicion of balanced ischemia is noted, and further non-invasive coronary evaluation required, PET can be used, without diversion from PET.
- Prior alternative perfusion (MPI or CMR) imaging resulted in an indeterminate evaluation for CAD.
- Cardiac positron emission tomography (PET) can characterize myocardial blood flow by perfusion scanning with either rubidium-82 (Rb-82) or nitrogen-13 (N-13) ammonia.

- PET can identify regions of myocardial viability with hibernating myocardium (viable, with poor flow and contractility) by imaging with fluorine18 (F-18) fluorodeoxyglucose (FDG or 18-FDG) for this purpose.
- PET poses a reduced radiation burden (2 - 3 mSv) compared to stress myocardial perfusion imaging (MPI) with technetium-based tracers (7 - 24 mSv), the short half-life of PET tracers does not work well for exercise stress testing.
- PET can be use useful in the evaluation of inflammation: (e.g., evaluation and therapy monitoring in members with sarcoidosis, after documentation of cardiac involvement by echo or electrocardiography (ECG), in place of, or subsequent to CMR if needed to help with an uncertain diagnosis.

Coronary application of PET includes evaluation of stable memberss without known CAD, who fall into two categories:

- Asymptomatic, for whom global risk of CAD events can be determined from coronary risk factors, using calculators available online.
- Symptomatic, for whom we estimate the pretest probability that their chest-related symptoms are due to clinically significant (≥ 50%) CAD (below):

**Three types of chest pain or discomfort**

- Typical angina (definite) Defined as including all of the following characteristics*:
    - Substernal chest pain or discomfort with characteristic quality and duration
    - Provoked by exertion or emotional stress
    - Relieved by rest and/or nitroglycerin.
- Atypical angina (probable) Has only 2 of the above characteristics*.
- Non-anginal chest pain Has only 0-1 of the above characteristics*.

Once the type of chest pain has been established from the medical record, the pretest probability of significant CAD is estimated from the Diamond Forrester score for pretest probability of coronary artery disease (see below Table 1), recognizing that additional coronary risk factors could increase pretest probability.

**Determination of Pretest Probability for Coronary Artery Disease (CAD)**

**Table 1:** Determination of Pretest Probability for Coronary Artery Disease Based on Age, Sex, and Symptoms (Source: American College of Cardiology Criteria for Pretest Probability of Coronary Artery Disease (CAD).

The following risk assessment may be used to determine pre-test probability of coronary artery disease:

| Age (years) | Sex | Typical/Definite Angina Pectoris | Atypical/Probable Angina Pectoris | Non-anginal Chest Pain | Asymptomatic |
|---|---|---|---|---|---|
| ≤ 39 | Men | Intermediate | Intermediate | Low | Very low |
| | Women | Intermediate | Very low | Very low | Very low |
| 40 – 49 | Men | High | Intermediate | Intermediate | Low |
| | Women | Intermediate | Low | Very low | Very low |
| 50 – 59 | Men | High | Intermediate | Intermediate | Low |
| | Women | Intermediate | Intermediate | Low | Very low |
| ≥ 60 | Men | High | Intermediate | Intermediate | Low |
| | Women | High | Intermediate | Intermediate | Low |

| |
|---|
| Very low: Less than 5% pretest probability of CAD<br>Low: Between 5% and 10% pretest probability of CAD<br>Intermediate: Between 10% and 90% pretest probability of CAD<br>High: Greater than 90% pretest probability of CAD |

Adapted from: Wolk MJ, Bailey SR, Doherty JU et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 Multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease. Journal of the American College of Cardiology 2014; 63(4): 380-406.

Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. Journal of the American College of Cardiology 2010;56(22):1864-1894.

Myocardial metabolic PET imaging does not meet the definition of medical necessity for screening for coronary artery disease.

**Additional information:**

**Definitions of Coronary Artery Disease**

Percentage stenosis refers to diameter stenosis when angiography is the method and can be estimated or measured using angiography or more accurately with intravascular ultrasound (IVUS).

- Coronary artery calcification is a marker of risk, as measured by Agatston score on coronary artery calcium imaging. It is not a diagnostic tool so much as it is a risk stratification tool.Its incorporation into global risk can be achieved by using the MESA risk calculator.
- Ischemia-producing disease (also called hemodynamically or functionally significant disease, for which revascularization might be appropriate) generally implies at least one of the following:
    - Suggested by percentage diameter stenosis ≥ 70% by angiography; borderline lesions are 40 - 70%
    - For a left main artery, suggested by a percentage stenosis ≥ 50% or minimum lumen cross sectional area on IVUS ≤ 6 square mm
    - Fractional flow reserve (FFR) ≤ 0.80 for a major vessel
    - Instantaneous wave-free ratio (iFR) ≤ 0.89 for a major vessel
    - Demonstrable ischemic findings on stress testing (ECG or stress imaging), that are at least mild in degree
- A major vessel would be a coronary vessel that would be amendable to revascularization, if it were indicated. This assessment is made based on the diameter of the vessel and/or the extent of myocardial territory served by the vessel.
- FFR (fractional flow reserve) is the distal to proximal pressure ratio across a coronary lesion during maximal hyperemia induced by either intravenous or intracoronary adenosine. Less than or equal to 0.80 is considered a reduction in coronary flow.
- Instantaneous wave-free ratio (iFR) measures the ratio of distal coronary to aortic pressure during the wave free period of diastole, with a value ≤ 0.89 considered hemodynamically significant.

**Anginal Equivalent**

Development of an anginal equivalent (e.g., shortness of breath, fatigue, or weakness) either with or without prior coronary revascularization should be based upon the documentation of reasons to suspect

that symptoms other than chest discomfort are not due to other organ systems (e.g., dyspnea due to lung disease, fatigue due to anemia), by presentation of clinical data such as respiratory rate, oximetry, lung exam. (as well as d-dimer, chest CTA) and/or pulmonary function tests (PFTs) when appropriate) and then incorporated into the evaluation of coronary artery disease as would chest discomfort. Syncope per se is not an anginal equivalent.

### Global Risk of Cardiovascular Disease (coronary disease (CAD))

Global risk of CAD is defined as the probability of manifesting cardiovascular disease over the next 10 years and refers to asymptomatic members without known cardiovascular disease. It should be determined using one of the cardiac risk calculators below. A high risk is considered greater than 20% risk of a cardiovascular event over the ensuing 10 years. High global risk by itself generally lacks scientific support as an indication for stress imaging. There are rare exemptions, such as members requiring IC antiarrhythmic drugs, who might require coronary risk stratification prior to initiation of the drug, when global risk is moderate or high.

**CAD Risk—Low**:10-year absolute coronary or cardiovascular risk less than 10%.

**CAD Risk—Moderate**: 10-year absolute coronary or cardiovascular risk between 10% and 20%.

**CAD Risk—High**: 10-year absolute coronary or cardiovascular risk of greater than 20%.

### Duke Treadmill Score

- The equation for calculating the Duke treadmill score (DTS) is, DTS = exercise time in minutes - (5 x ST deviation in mm or 0.1 mV increments) - (4 x exercise angina score), with angina score being 0 = none, 1 = non limiting, and 2 = exercise-limiting.
- The score typically ranges from -25 to +15. These values correspond to low-risk (with a score of≥ +5), intermediate risk (with scores ranging from - 10 to + 4), and high-risk (with a score of ≤ -11) categories.

**Online cardiac risk calculator and assessment tools**

The links for the online cardiac risk calculator and assessment tools are to an outside source and is provided for your convenience. Use of the links and related calculator and assessment tools are subject to the terms and conditions of the website and is not warranted, maintained or affiliated with Florida Blue.

Framingham Risk Score Calculator: http://www.medcalc.com/heartrisk.html

Reynolds Risk Score: http://www.reynoldsriskscore.org/

Pooled Cohort Risk Assessment Equations: http://clincalc.com/Cardiology/ASCVD/PooledCohort.aspx

ACC/AHA Risk Calculator:http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/

MESA Risk Calculator (With addition of coronary artery calcium score, for CAD-only risk.): https://www.mesa-nhlbi.org/MESACHDRisk/MesaRiskScore/RiskScore.aspx

### Documentation Requirements

Documentation containing the medical necessity of the myocardial imaging positron emission tomography (PET) results (e.g., images, clinical reports) should be maintained in the member's medical record. Documentation may be requested as part of the review process.

## LOINC Codes

The following information may be required documentation to support medical necessity: physician history and physical, physician progress notes, plan of treatment and reason for myocardial imaging positron emission tomography (PET).

| Documentation Table | LOINC Codes | LOINC Time Frame Modifier Code | LOINC Time Frame Modifier Codes Narrative |
|---|---|---|---|
| Physician history and physical | 28626-0 | 18805-2 | Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim |
| Attending physician progress note | 18741-9 | 18805-2 | Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim |
| Plan of treatment | 18776-5 | 18805-2 | Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim |
| Exercise stress test study | 18752-6 | 18805-2 | Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim |

## BILLING/CODING INFORMATION:

### CPT Coding

| | |
|---|---|
| 78429 | Myocardial imaging, positron emission tomography (PET), metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), single study; with concurrently acquired computed tomography transmission scan |
| 78430 | Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); single study, at rest or stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan |
| 78431 | Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); multiple studies at rest and stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan |
| 78432 | Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg, myocardial viability) |
| 78433 | Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when |

| | |
|---|---|
| | performed), dual radiotracer (eg, myocardial viability); with concurrently acquired computed tomography transmission scan |
| 78434 | Absolute quantitation of myocardial blood flow (AQMBF), positron emission tomography (PET), rest and pharmacologic stress (List separately in addition to code for primary procedure) |
| 78459 | Myocardial imaging, positron emission tomography (PET), metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), single study |
| 78491 | Myocardial imaging, positron emission tomography (PET), perfusion; single study including ventricular wall motion[s] and/or ejection fraction[s], when performed); single study, at rest or stress (exercise or pharmacologic) |
| 78492 | Myocardial imaging, positron emission tomography (PET), perfusion study including ventricular wall motion[s] and/or ejection fraction[s], when performed); multiple studies at rest and/or stress (exercise or pharmacologic) |

## REIMBURSEMENT INFORMATION:

PET scans are performed using a camera that has either been approved or cleared for marketing by the Food and Drug Administration (FDA) to image positron annihilation gamma photons in the body.

PET scans are performed using FDA approved or radiopharmaceutical (tracer, radiotracer) (e.g., ammonia N-13, Fluorodeoxyglucose F-18 FDG, Rubidium Rb-82). The radiopharmaceutical may be manufactured on site, or manufactured at a regional delivery center with delivery to the institution performing the PET scan. When the radiopharmaceutical is provided by an outside distribution center, there may be a separate charge for both the radiopharmaceutical and transportation of the radiopharmaceutical.

## PROGRAM EXCEPTIONS:

Coverage for the radiology services referenced in this guideline performed and billed in an outpatient or office location will be handled through the Radiology Management program for select products. The National Imaging Associates (NIA) will determine coverage for these services for select products. Refer to member's contract benefits.

**Federal Employee Plan (FEP):** FEP is excluded from the National Imaging Associates (NIA) review; follow FEP guidelines.

**Medicare Advantage products:**

The following Local Coverage Determination (LCD) was reviewed on the last guideline reviewed date: Cardiology-non-emergent outpatient testing: exercise stress test, stress echo, MPI SPECT and cardiac PET, and (L36209) located at fcso.com.

The following National Coverage Determinations (NCDs) were reviewed on the last guideline reviewed date: PET (FDG) for Myocardial Viability (220.6.8), PET for Perfusion of the Heart (220.6.1) and FDG PET for Myocardial Viability (220.3.8) located at cms.gov.

## DEFINITIONS:

**Equivocal:** of uncertain nature or classification.

**Myocardial metabolic PET imaging:** the cardiac muscle is imaged using data received from positron-emitting radionuclides administered to the patient. The collision of the positrons emitted by the radionuclide with the negatively charged electrons normally present in tissue is then computer synthesized to produce an image, usually in color. This image will show the presence or absence of ischemic cardiac tissue.

**Myocardial perfusion PET imaging:** imaging of the cardiac muscle is performed using data received from positron-emitting radionuclides administered to the patient. Collision of the positrons emitted by the radionuclide with the negatively charged electrons normally present in tissue is then computer synthesized to produce an image, usually in color. The procedure may be performed at rest or stress.

## RELATED GUIDELINES:

**Cardiac Radionuclide Imaging (Myocardial Perfusion Imaging, Cardiac Blood Pool Imaging) 04-78000-19**

**FDG-SPECT, 04-78000-15**

**Positron Emission Tomography (PET Scan) Oncologic Applications, 04-78000-17**

**Positron Emission Tomography (PET Scans) Miscellaneous Applications, 04-78000-18**

## OTHER:

Other names used to report positron emission tomography (PET):

Positron emission transverse tomography (PETT)
Positron emission coincident imaging (PECI)

**Abbreviations**
CAD = coronary artery disease
FDA = Food and Drug Administration

MPI= myocardial perfusion imaging

MRI= magnetic resonance imaging

SPECT= single photon emission computed tomography

## REFERENCES:


1. Agency for Healthcare Research and Quality (AHRQ-National Guideline Clearinghouse-Procedure Guideline for Myocardial Perfusion Imaging, 10/24/05.
2. Al-Khatib SM, Stevenson WG, Ackerman MJ et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2018 Oct;15(10): e190-e252.
3. American College of Cardiology/American Heart Association Practice Guidelines-AAC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging, 2003.

4. American Society of Nuclear Cardiology-An Overview of Nuclear Cardiology (Myocardial Perfusion Imaging, Positron-Emission tomography (PET)), 2009.

5. Bacharach SL, Bax JJ, Case J et al. PET myocardial glucose metabolism and perfusion imaging: Part I-Guidelines for patient preparation and data acquisition. Journal of Nuclear Cardiology 2003; 10(5): 543-556.

6. Beanlands RS, Chow BJ, Dick A et al. CCS/CAR/CANM/CNCS/Can SCMR Joint Position Statement on Advanced Non-invasive Cardiac Imaging Using Positron Emission Tomography, Magnetic Resonance Imaging and Multi-Detector Computed Tomographic Angiography in the Diagnosis and Evaluation of Ischemic Heart Disease – Executive Summary. Canadian Journal of Cardiology 2007; 23(2):107-119.

7. Blankstein R, Osborne M, Naya M, Waller A et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014 Feb 4;63(4):329-336

8. Brindis RG, Douglas PS, Hendel RC et al. ACC/ASNC Appropriateness Criteria for Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging (SPECT MPI)-A report of the American College of Cardiology foundation quality strategic directions committee appropriateness criteria working group and the American Society of Nuclear Cardiology. Journal of the American College of Cardiology 2005; 46(8): 1587-1605.

9. Des Prez RD, Shaw LJ, Gillespie RL et al. Cost-effectiveness of myocardial perfusion imaging: a summary of the currently available literature. Journal of Nuclear Cardiology 2005; 12(6): 750-9.

10. Di Bella EV, Kadrmas DJ, Christian PE. Feasibility of dual-isotope coincidence/single-photon imaging of the myocardium. Journal of Nuclear Medicine 2001; 42(6): 944-950.

11. Di Carli MF, Dorbala S, Meserve J et al. Clinical myocardial perfusion PET/CT. Journal of Nuclear Medicine 2007; 48(5): 783-793.

12. Doherty JU, Kort S, Mehran R et al. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2017 Appropriate use criteria for multimodality imaging in valvular heart disease. Journal of the American College of Cardiology 2017.

13. Eagle KA, Berger PB, Calkins H et al. ACC/AHA guideline update on perioperative cardiovascular evaluation for noncardiac surgery-A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to update the 1996 guidelines on perioperative cardiovascular evaluation for noncardiac surgery), 2002.

14. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126: e354-e741.

15. Fraker TE, Fihn SD. 2007 Chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina. Journal of the American College of Cardiology 2007; 40(23): 2264-2274.

16. Gibbons, Balady GJ, Bricker J T et al. ACC/AHA 2002 guideline update for exercise testing. Circulation 2002; 106:1883.

17. Gräni C, Buechel RR, Kaufmann PA et al. Multimodality imaging in individuals with anomalous coronary arteries. JACC Cardiovasc Imaging 2017 Apr;10(4):471-481.

18. Greenland P, Smith SC, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people-Role of traditional risk factors and noninvasive cardiovascular tests. Circulation 2001; 104:1863-1867.

19. Grundy SM, Pasternak R, Greenland P et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. Circulation 1999; 100:1481-1492.

20. Habib G, Lancellotti P, Antunes MJ et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015 Nov 21;36(44):3075-3128.

21. Hendel RC, Budoff M J, Cardella JF et al. ACC/AHA/ACR/ASE/ASNC/HRS/NASCI/RSNA/SAIP/SCAI/SCCT/SCMR/SIR 2008 Key data elements and definitions for cardiac imaging-American College of Cardiology/American Heart Association Task Force on clinical data standards. Journal of the American of Cardiology 2008; 20(10): 1-34.

22. Hendel RC, Wackers RJ, Berman DS et al. American Society of Nuclear Cardiology consensus statement: Reporting of radionuclide myocardial perfusion imaging studies. Journal of Nuclear Cardiology 2006; 13(6): e152-6.

23. Hesse B, Tagil K, Cuocolo A et al. EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. European Journal of Nuclear Medicine and Molecular Imaging 2005; 32(7): 855-897.

24. Klocke FJ, Baird MG, Bateman TM et al. ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging, 2003.

25. Lentine KL, Costa SP, Weir MR et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of Transplantation, and National Kidney Foundation. Circulation 2012 Jul 31;126(5):617-663.

26. Machac J, Bacharach SL, Bateman TM et al. Positron emission tomography myocardial perfusion and glucose metabolism imaging. Journal of Nuclear Cardiology 2006; 13 (6): e121-e151.

27. Merhige ME, Breen WJ Shelton V et al. Impact of myocardial imaging with PET and (82) Rb on downstream invasive procedure utilization, costs, and outcomes in coronary disease management. Journal of Nuclear Cardiology 2007; 48(7): 1069-1076.

28. National Imaging Associates, Inc.Clinical Guidelines PET Scan, Heart (Cardiac),2019.

29. Patel MR, White RD, Abbara S et al. 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: A Joint Report of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Foundation Appropriate Use Criteria Task Force. J Am Coll Cardiol 2013;61(21):2207-2231.

30. Reiffel JA, Camm AJ, Belardinelli L et al. The HARMONY Trial: combined Ranolazine and Dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism. Circ Arrhythm Electrophysiol 2015 Oct;8(5):1048-1056.

31. Sato H, Iwasaki T, Toyama T et al. Prediction of functional recovery after revascularization in coronary artery disease using (18) F-FDG and (123) I-BMIPP SPECT. Chest 2000; 117(1): 65-72.

32. Schelbert HR, Beanlands R, Bengel F et al. PET myocardial perfusion and glucose metabolism imaging: Part 2-Guidelines for interpretation and reporting. Journal of Nuclear Cardiology 2003; 10(5): 557-571.

33. Siebelink HM, Blanksma PK, Crijns HJ et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. Journal of the American College of Cardiology 2001; 37(1): 81-88.

34. Tarakji KG, Brunken R, McCarthy PM et al. Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction. Circulation 2006; 113: 230-237.

35. Tilkemeier PL, Cooke CD, Ficaro EP et al. American Society of Nuclear Cardiology information statement: Standardized reporting matrix for radionuclide myocardial perfusion imaging. Journal of Nuclear Cardiology 2006; 13:e157-71.

36. Young LH, Wackers FJ, Chyun DA et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes. The Journal of the American Medical Association 2009; 301(15): 1547-1555.

37. Zipes DP, Camn AJ, Borggrefe M et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-executive summary. Circulation 2006; 114; 1088-1132.

38. Vita T, Okada DR, Veillet-Chowdhury M et al. Complementary value of cardiac magnetic resonance imaging and positron emission tomography/computed tomography in the assessment of cardiac sarcoidosis. Circ Cardiovasc Imaging 2018 Jan;11(1): e007030.

39. Wolk MJ, Bailey SR, Doherty JU et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Stable Ischemic Heart Disease A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. Journal of the American College of Cardiology 2013; 63 (4): 380-406.

40. Yancy CW, Jessup M, Bozkurt B et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017;136(6):e137-e161.

## COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the BCBSF Medical Policy & Coverage Committee on 02/27/20.

## GUIDELINE UPDATE INFORMATION:

| | |
|---|---|
| 10/15/03 | Annual review. Developed separate policy for PET Scans Cardiac Applications. |
| 01/01/04 | 2004 HCPCS update: deleted Q4078 and replaced with A9526. |
| 03/15/05 | Added program exception for Health Options, Blue Care, and Medicare Advantage products. |
| 12/15/05 | Revised the when services are covered section; ICD-9-CM diagnoses codes (expand the code range for coronary atherosclerosis, revise the descriptor for: V45.09 and V45.89).<br><br>Revised reimbursement information section; revise IDC-9 diagnoses code description, deleted FDA statement regarding the camera and radiotracer. Revised program exception section; add 78459 to NIA's general statement, and updated references. No longer scheduled for review. |

| | |
|---|---|
| 03/15/06 | HCPCS update, deleted G0030, G0031, G0032, G0033, G0034, G0035, G0036, G0037, G0038, G0039, G0040, G0041, G0042, G0043, G0044, G0045, G0046, G0047, and G0230. |
| 06/15/06 | Added A9552. Revised program exception; NIA statement, and updated references. |
| 07/01/07 | Reformatted guideline. Revised coverage statement for PET myocardial imaging. Revised reimbursement statement. Deleted generation of automated data (78890, 78891) reimbursement statement. Added HCPCS code A9555. Deleted HCPCS code Q3000. Added information regarding myocardial perfusion imaging and myocardial viability to section entitled “Other”, and updated references. |
| 01/21/08 | Updated Program Exceptions. |
| 07/15/08 | Scheduled reviewed. No change in position statement. Changed PET myocardial imaging to PET cardiac imaging. Added code S8085, and updated references. |
| 05/21/09 | Removed Federal Employee Plan (FEP) from BCBSF Radiology Management program exception statement. Added FEP program exception statement: FEP is excluded from the National Imaging Associates (NIA) review; follow FEP guidelines. |
| 07/01/09 | Updated BCBSF Radiology Management program exception; added BlueSelect. |
| 07/15/09 | Annual review. Revised description. Revised position statements to include medically necessary indications for myocardial perfusion PET imaging and myocardial metabolic PET imaging. Deleted S8085. Added guideline specific definitions. Added program exception for Medicare Advantage products. Added related guideline link for FDG-SPECT. Updated references. |
| 01/01/10 | Revised BCBSF Radiology Management program exception section. |
| 06/15/10 | Annual review. Revised Medicare Advantage products program exception; ICD-9 code descriptor (428.20 – 428.23, 428.30 – 428.33, and 428.40 – 428.43). Updated references. |
| 10/01/11 | Revision; Formatting changes. |
| 06/15/12 | Scheduled review; deleted Medicare ICD-9 codes and updated references. |
| 01/01/14 | Review. Updated program exception and references. |
| 04/15/17 | Code update; deleted A9526, A9552 and A9555. |
| 01/01/18 | Annual HCPCS code update. Added 0482T. |
| 09/15/18 | Revision; revised position statement. Removed scan from guideline subject. Updated references. |
| 01/01/20 | Annual HCPCS code update. Added (78429, 78430, 78431, 78432, 78433, 78434). Revised code descriptor (78459, 78491, 78492). Deleted 0482T. |
| 03/15/20 | Review/Revision. Revised and expanded indications and criteria. Revised description and definitions and format position statement. Updated references. |

| | |
|---|---|
| 03/25/20 | Revised billing/coding section. |